Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial

British Journal of Cancer

Volumn 110, Issue 10, 2014, Pages 2427-2433

  Ediebah, D E ^a   Coens, C ^a   Zikos, E ^a   Quinten, C ^a,b   Ringash, J ^c   King, M T ^d   Schmucker Von Koch, J ^e   Gotay, C ^f   Greimel, E ^g   Flechtner, H ^h   Weis, J ⁱ   Reeve, B B ^j   Smit, E F ^k   Taphoorn, M J B ^k   Bottomley, A ^a  

^a EORTC DATA CENTER   (Belgium)

^b EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF REGENSBURG   (Germany)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g MEDICAL UNIVERSITY OF GRAZ   (Austria)

^h OTTO VON GUERICKE UNIVERSITY   (Germany)

ⁱ UNIVERSITY OF FREIBURG   (Germany)

^j IL   (United States)

^k VU UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DYSPHAGIA; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PAIN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; QUALITY OF LIFE; RATING SCALE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CLINICAL TRIALS, PHASE III AS TOPIC; DEGLUTITION DISORDERS; DEOXYCYTIDINE; HUMANS; INTERPERSONAL RELATIONS; LUNG NEOPLASMS; MULTICENTER STUDIES AS TOPIC; NAUSEA; PACLITAXEL; PAIN; PALLIATIVE CARE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; QUALITY OF LIFE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 84900535836     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.208     Document Type: Article

References (38)

1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, De Haes JCJM, Kaasa S, Klee MC, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw KCA, SullivanM, Takeda F (1993) The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365-376.
2. Akin S, Can G, Aydiner A, Ozdilli K, Durna Z (2010) Quality of life, symptom experience and distress of lung cancer patients undergoing chemotherapy. Eur J Oncol Nurs 14: 400-409.
3. Albain KS, Crowley JJ, LeBlanc M, Livingston RB (1991) Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol 9: 1618-1626.
4. Basch E, Abernethy AP, Mullins CD, Reeve BB, Smith ML, Coons SJ, Sloan J, Wenzel K, Chauhan C, Eppard W, Frank ES, Lipscomb J, Raymond SA, Spencer M, Tunis S (2012) Recommendations for incorporating patientreported ou tcomes into clinical comparative-effectiveness research in adult oncology. J Clin Oncol 30: 4249-4255.
5. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M (1994) The EORTC QLQ-LC13: A modular sup plement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 30A: 635-642.
6. Braun DP, Gupta D, Grutsch JF, Staren ED (201 1a) Can changes in health related quality of life scores predict survival in stages III and IV colorectal cancer HealthQual Life Outcomes 9: 62.
7. Braun DP, Gupta D, Staren ED (2011b) Quality of life assessment as a predictor of survival in non-small cell lung cancer. BMC Cancer 11: 353.
8. Concato J, Peduzzi P, Holfold TR, Feinstein AR (1995) Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy. J Clin Epidemiol 48: 1495-1501.
9. Cox DR (1972) Regression models and life tables. J R Stat Soc 4: 187-220.
10. Efficace F, Botto mley A, Smit EF, Lianes P, Legrand C, Debruyne C, Schramel F, Smit HJ, Gaafar R, Biesma B, Manegold C, Coens C, Giaccone G, Van Meerbeeck J. EORTC Lung Cancer Group and Quality of Life Unit (2006) I s a patient?s self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol 17: 1698-1704.
11. EME A/CHMP/EWP/139391/2004 (2004) Committee for Medicinal Products for Human use. (CHMP). Reflection Paper on the Regulatory Guidance for the Use of Health-Related Quality of Life (HRQL) Measures in the Evaluation of Medicinal Products.
12. Eton DT, Fairclough DL, Cella D, Yount SE, Bonomi P, Johnson DH. Eastern Cooperative Oncology Group (2003) Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those p redicted by baseline report: Results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol 21: 1536-1543.
13. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
14. Ganz PA, Lee JJ, Siau J (1991) Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer 67: 3131-3135.
15. Gotay CC, Kawamoto CT, Bottomley A, Efficace F (2008) The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol 26: 1355-1363.
16. Gralla RJ 2004 Quality-of-life considerations in patients with advanced lung cancer: Effect of topotecan on symptom palliation and quality of life Oncologist 6 14-24.
17. Groenvold M, Klee MC, Sprangers MA, Aaronson NK (1997) Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. J Clin Epidemiol 50: 441-450.
18. Gupta D, Braun DP, Staren ED (2012) Association between changes in quality of life scores and survival in non-small cell lung cancer patients. Eur J Cancer Care (Engl) 21: 614-622 .
19. Herndon 2nd JE, Fleishman S, Kornblith AB, Kosty M, Green MR, Holland J (1999) Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma Cancer 85: 333-3 40.
20. Johnson JR, Williams G, Pazdur R (2003) End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21: 1404-1411.
21. Kvale PA, Simoff M, Prak ash UB. American College of Chest Physicians (2003) Lung cancer. Palliative care. Chest 123: 284S-311S.
22. Lipscomb J, Gotay CC, Snyder CF (2007) Patient-reported outcomes in cancer: A review of recent research and policy initiatives. CA Cancer J Clin 57: 278-300.
23. Maione P, Perrone F, Gallo C, Manzione L, Piantedosi F, Barbera S, Cigolari S, Rosetti F, Piazza E, Robbiati SF, Bertetto O, Novell o S, Migliorino MR, Favaretto A, Spatafora M, Ferraù F, Frontini L, Bearz A, Repetto L, Gridelli C, Barletta E, Barzelloni ML, Iaffaioli RV, De Maio E, Di Maio M, De Feo G, Sigoriello G, Chiodini P, Cioffi A, Guardasole V, Angelini V, Ro s si A, Bilancia D, Germano D, Lamberti A, Pontillo V, Brancaccio L, Renda F, Romano F, Esani G, Gambaro A, Vinante O, Azzarello G, Clerici M, Bollina R, Belloni P, Sannicolò M, Ciuffreda L, Parello G, Cabiddu M, Sacco C, Sibau A, Porcile G, Castiglione F, Ostellino O, Monfardini S, Stefani M, Scagliotti G, Selvaggi G, De Marinis F, Martelli O, Gasparini G, Morabito A, Gattuso D, Colucci G, Galetta D, Giotta F, Gebbia V, Borsellino N, Testa A, Malaponte E, Capuano MA, Angiolillo M, Sollitto F, Tirelli U, Sp azzapan S, Adamo V, Altavilla G, Scimone A, Hopps MR, Tartamella F, Ianniello GP, Tinessa V, Failla G, Bordonaro R, Gebbia N, ValerioMR, D?AprileM, Veltri E, Tonato M, Darwish S, Romito S, Carrozza F, Barni S, Ardizzoia A, Corradini GM, Pavia G, Belli M, Colantuoni G, Galligioni E, Caffo O, Labianca R, Quadri A, Cortesi E, D ?Auria G, Fava S, Calcagno A, Luporini G, Locatelli MC, Di Costanzo F, Gasperoni S, Isa L, Candido P, Gaion F, Palazzolo G, Nettis G, Annamaria A, Rinaldi M, Lopez M, Felletti R, Di Negro GB, Rossi N, Calandriello A, Maiorino L, Mattioli R, Celano A, Schiavon S, Illiano A, Raucci CA, Caruso M, Foa P, Tonini G, Curcio C, Cazzaniga M (2005) Pretreatment quality of life and functional status assessment significantly predict survival of e l derly patients with advanced nonsmall-cell lung cancer receiving chemotherapy: A prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol 23: 6865-6872.
24. Mountain CF (1997) Revis ions in the international system for staging lung cancer. Chest 111: 1710-1717.
25. Movsas B, Moughan J, Sarna L, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, Machtay M, Wasserman T, Brune r DW (2009) Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: An analysis of RTOG 9801. J Clin Oncol 27: 5816-5822.
26. National Cancer Instit ute (2008) The Nation?s Investment in Cancer Research: A plan and budget proposal for Fiscal Year 2008. NIH Publication No. 06-6090. Available at http://plan.cancer.gov/plan-overview.shtml.
27. Osoba D, Zee B, Pater J, Warr D, Kaizer L, Latreille J (1994) Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 3: 353-364.
28. Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16: 139-144.
29. Peduzzi P, Concato J, Feinstein AR, Holford TR (1995) Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 48: 1503-1510.
30. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR (1996) A simulation study of the number of events p er variable in logistic regression analysis. J Clin Epidemiol 49: 1373-1379.
31. Quinten C, Coens C, Mauer M, Comte S, Sprangers MA, Cleeland C, Osoba D, Bjordal K, Bottomley A. EORTC Clinica l Groups (2009) Baseline quality of life as a prognostic indicator of survival: A meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 10: 865-871.
32. Scott NW, Fayers PM, Aaronson NK, Bottomley A, De Graeff A, Groenvold M, Gundy CM, Koller M, Petersen MA, Sprangers MAG. on behalf of the EORTC Quality of Life Group (2008) EORTC QLQ-C30 Reference Values. EORTC Publications, 2008: Brussels, Belgi um.
33. Sloan JA, Zhao X, Novotny PJ, Wampfler J, Garces Y, Clark MM, Yang P (2012) Relationship between deficits in overall quality of life and non-small-cell lung cancer survival. J Clin Oncol 30: 1498-1504.
34. Smit EF, Van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F, Smit H, Gaafar R, Biesma B, Manegold C, Neymark N, Giaccone G.European Organization for Research and Treatment of Cancer Lung Cancer Group (2003) Three-arm randomised study of two Cisplatin-based regimens and Paclitaxel plus Gemcitabine in advanced Non-Small Cell Lung Cancer: A phase III trial of the European Organization for Research and Treat ment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 21: 3909-3917.
35. SuaerbreiW Schumacher M 1992A bootstrap resampling procedure for model building: Application to the Cox regression model Stat Med 11 2093-2109.
36. Tishelman C, Lövgren M, Broberger E, Hamberg K, Sprangers MA (2010) Are the most distressing concerns of patients with inoperable lung cancer adequately assessed A mixed-methods analysis . J Clin Oncol 28: 1942-1949.
37. United States Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH) (2007) Guidance for Industry-Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Available at http://www.fda.gov/downloads/Drugs/Guidances/ UCM193282.pdf.
38. Vittinghoff E, McCulloch CE (2007) Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 165: 710-718.